Umedica Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UMEDICA
UMEDICA has nineteen approved drugs.
Summary for Umedica
| US Patents: | 0 |
| Tradenames: | 17 |
| Ingredients: | 17 |
| NDAs: | 19 |
Drugs and US Patents for Umedica
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Umedica | OLMESARTAN MEDOXOMIL | olmesartan medoxomil | TABLET;ORAL | 207135-003 | Jul 18, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Umedica | ROSUVASTATIN CALCIUM | rosuvastatin calcium | TABLET;ORAL | 207626-002 | Apr 9, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Umedica Labs Pvt | OXCARBAZEPINE | oxcarbazepine | TABLET;ORAL | 218341-001 | Apr 29, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Umedica | CARBAMAZEPINE | carbamazepine | TABLET, EXTENDED RELEASE;ORAL | 216594-003 | Aug 18, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Umedica | ROSUVASTATIN CALCIUM | rosuvastatin calcium | TABLET;ORAL | 207626-003 | Apr 9, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Umedica | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 213853-003 | Aug 19, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
